Topical Triple-Agent FDC Gel Found Most Effective and Safe for Moderate-to-Severe Acne in New Meta-Analysis

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-07 02:00 GMT   |   Update On 2024-09-07 02:00 GMT
Advertisement

USA: Among nearly 20 different agents and treatment combinations, the topical triple-agent fixed-dose combination (FDC) gel proved to be the most effective for treating moderate-to-severe acne, according to a network meta-analysis (NMA). The findings were published online in the Journal of Drugs in Dermatology.

There are several treatment options available for managing moderate-to-severe acne. Topical treatments, such as the triple-agent FDC gel, are often preferred due to their targeted application and reduced risk of systemic side effects compared to oral medications. This gel combines proven acne-fighting agents that work synergistically to address multiple aspects of acne pathology, including inflammation, bacterial growth, and excess oil production.

Advertisement

Julie C Harper, The Dermatology and Skin Care Center of Birmingham, AL, and colleagues aimed to systematically examine the comparative effectiveness (efficacy/safety) of moderate-to-severe acne treatments.

For this purpose, the researchers conducted a systematic literature review (SLR) to identify randomized controlled trials involving at least four weeks of treatment—whether topical, oral, physical, or a combination—for moderate-to-severe facial acne in patients aged nine years and older. The study aimed to evaluate efficacy outcomes, including the percentage of patients achieving a two-grade reduction from baseline and those classified as “clear” or “almost clear” for global severity score (treatment success), as well as the absolute changes in inflammatory (ILs) and noninflammatory lesion counts (NILs).

A random-effects network meta-analysis was then performed to assess these efficacy outcomes, with treatments ranked based on posterior rank plots and surface under the cumulative ranking values. The SLR/NMA included a total of 85 studies.

The researchers reported the following findings:

  • Topical triple-agent fixed-dose combination gel (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) and combinations of double-agent fixed-dose topical treatments with oral antibiotics (TOA3) consistently ranked in the top 3 treatments.
  • Topical triple-agent FDC gel was numerically superior to TOA3 for treatment success (log-odds ratios: 1.84) and 1.69 vs placebo/vehicle).
  • TOA3 was numerically superior to topical triple-agent FDC gel for reduction of ILs (mean difference: -8.21) and -10.40 versus placebo/vehicle) and NILs (mean difference: -13.41 and -17.74 versus placebo/vehicle).

The research team concluded that the topical triple-agent fixed-dose combination (FDC) gel was more effective than all other treatments for moderate-to-severe acne. Its use helps reduce the reliance on oral antibiotics, which in turn lowers the risk of developing antibiotic resistance.

Additionally, the findings indicate that combining an oral antibiotic with a double-agent FDC gel does not provide significant advantages over using the triple-agent FDC gel alone.

Reference:

Harper JC, Baldwin H, Choudhury SP, Rai D, Ghosh B, Aman MS, Choudhury AR, Dutta SK, Dey D, Bhattacharyya S, Lin T, Joseph G, Dashputre AA, Tan JKL. Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis. J Drugs Dermatol. 2024 Apr 1;23(4):216-226. doi: 10.36849/JDD.8148. PMID: 38564399.


Tags:    
Article Source : Journal of Drugs in Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News